Bioverativ Inc (NASDAQ:BIVV) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. Eleven analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $64.20.
A number of equities research analysts have weighed in on the company. William Blair restated a “hold” rating on shares of Bioverativ in a research report on Thursday, March 8th. Argus restated a “hold” rating on shares of Bioverativ in a research report on Wednesday, January 24th. Finally, Credit Suisse Group restated a “neutral” rating on shares of Bioverativ in a research report on Wednesday, January 24th.
Bioverativ remained flat at $$104.98 during trading hours on Monday, according to Marketbeat Ratings. Bioverativ has a 52-week low of $48.14 and a 52-week high of $105.01.
Large investors have recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. bought a new position in shares of Bioverativ during the fourth quarter valued at about $105,000. American Assets Investment Management LLC bought a new stake in shares of Bioverativ in the fourth quarter worth about $108,000. Bailard Inc. bought a new stake in shares of Bioverativ in the fourth quarter worth about $216,000. Rehmann Capital Advisory Group bought a new stake in shares of Bioverativ in the fourth quarter worth about $241,000. Finally, Kazazian Asset Management LLC grew its stake in shares of Bioverativ by 11.5% in the fourth quarter. Kazazian Asset Management LLC now owns 5,201 shares of the biotechnology company’s stock worth $280,000 after purchasing an additional 538 shares during the last quarter. 97.18% of the stock is currently owned by hedge funds and other institutional investors.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.